Sana Biotechnology Announces FDA Clearance of Investigational …
Nov 9, 2023 · Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis
Sana Biotechnology Reports Third Quarter 2023 Financial Results …
SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today reported financial results and business highlights for the third quarter 2023.
Investor Relations | Sana Biotechnology, Inc
Dec 2, 2024 · The Investor Relations website contains information about Sana Biotechnology, Inc's business for stockholders, potential investors, and financial analysts.
Sana Biotechnology Announces Preclinical Data Published in …
SEATTLE, May 08, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Nature Biotechnology has published a paper titled “Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus ...
Sana Biotechnology to Present at November and December 2023 …
SEATTLE, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in …
Sana Biotechnology Announces Preclinical Data Published in …
Apr 13, 2023 · Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses
Sana Biotechnology Announces the Acceptance of Six Abstracts …
May 2, 2023 · Process improvements were made to the manufacturing of Sana’s CD8 targeted fusosome for in vivo CAR T therapy, resulting in enhanced resting T cell transduction and in vitro and in vivo tumor killing.
Sana Biotechnology, Inc News Releases
SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at five investor conferences in September.
Events and Presentations | Sana Biotechnology, Inc
Oct 1, 2024 · Sana Biotechnology at the H.C. Wainwright 26th Annual Global Investment Conference
Release Details - Sana Biotechnology, Inc
SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced preclinical data supporting the anti-tumor and immune evasion capabilities of allogeneic CAR T cells engineered with Sana’s proprietary hypoimmune (HIP ...